All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Certolizumab safety and efficacy in clinical practice

Jun 17, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in psoriasis.

A retrospective, multicenter, observational study of certolizumab pegol treatment in patients with plaque psoriasis has been published in the International Journal of Dermatology by Sahuquillo-Torralba et al.1 A total of 67 patients were evaluated in the study and were observed from the first dose of certolizumab until the date of the first missed dose.1 

Key learnings:

Absolute PASI <3 was achieved in 69%, 86%, and 92% of patients receiving certolizumab at Weeks 12, 24, and 52, respectively, with a drug survival rate of 85% in the first year. 

21% of patients discontinued certolizumab, the majority due to lack/loss of effectiveness. 

In 14 patients who initiated treatment during pregnancy and/or lactation, there were no recorded adverse events at the time of delivery or in the neonatal period, supporting guidelines that recommend the use of certolizumab as a first-line choice of biologic for patients planning pregnancy or breastfeeding. 

  1. Sahuquillo-Torralba A, Mansilla-Polo M, Pujol-Marco C, et al. Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group. Int J Dermatol. 2024. Online ahead of print. DOI: 10.1111/ijd.17238 


Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox